key: cord-0827714-72emhupx
authors: Zhu, Huanhuan; Zheng, Fang; Li, Linxuan; Jin, Yan; Luo, Yuxue; Li, Zhen; Zeng, JingYu; Tang, Ling; Li, Zilong; Xia, Ningyu; Liu, Panhong; Han, Dan; Shan, Ying; Zhu, Xiaoying; Liu, Siyang; Xie, Rong; Chen, Yilin; Liu, Wen; Liu, Longqi; Xu, Xun; Wang, Jian; Yang, Huanming; Shen, Xia; Jin, Xin; Cheng, Fanjun
title: A Chinese host genetic study discovered IFNs and causality of laboratory traits on COVID-19 severity
date: 2021-09-30
journal: iScience
DOI: 10.1016/j.isci.2021.103186
sha: 89880487edde4f7fe812a5d9f67ce49c8066274e
doc_id: 827714
cord_uid: 72emhupx

The COVID-19 pandemic has caused over 220 million infections and 4.5 million deaths worldwide. Current risk factor cannot fully explain the diversity in disease severity. Here, we present a comprehensive analysis of a broad range of patients’ laboratory and clinical assessments to investigate the genetic contributions to COVID-19 severity. By performing GWAS analysis, we discovered several concrete associations for laboratory traits, and used Mendelian randomization (MR) analysis to further investigate the causality of traits on disease severity. Two causal traits, WBC counts and cholesterol levels, were identified based on MR study, and their functional genes are located at genes MHC complex and ApoE, respectively. Our gene-based and GSEA analysis revealed four interferon pathways, including type I interferon receptor binding and SARS coronavirus and innate immunity. We hope that our work will contribute to studying the genetic mechanisms of disease and serve as a useful reference for COVID-19 diagnosis and treatment. Keywords: COVID-19, Genome-wide association study, Mendelian randomization, GSEA analysis, MHC complex, ApoE gene, IFNs pathway

number of the studied traits, 5 variant-trait associations were significant signals (p-value < 5E-134 08/78 = 6.41E-10), 4 out of which were previously identified in either EUR, EAS, or both 135 populations (Table 2) . These associations include rs1801020 (F12, p-value = 4.13E-16) with 136 activated partial thromboplastin time (APTT), rs56393506 (LPA, p-value = 1.97E-14) with 137 lipoprotein-A (LpA), rs28946889 (UGT1A complex, p-value = 5.08E-14) with total bilirubin 138 levels (Tbil), and rs28946889 (UGT1A complex, p-value = 1.51E-16) with indirect bilirubin 139 levels (Ibil). The Manhattan plots and QQ-plots were drawn for APTT, LpA, and Ibil with the 140 CMplot package in R (Yin et al., 2021) and provided in Figure 4 . A novel association was 141 rs11032789 (EHF, p-value = 6.40E-10) with apoprotein A (apoA). Even though the association 142 between rs7412 (ApoE, p-value = 2.30E-08) and the LDL-C levels did not reach the study-wide 143 significance threshold, it had been widely identified in EUR, EAS, and CHN populations. The 144 association between rs9268517 (BTNL2, p-value = 4.05E-08) with the WBC counts did not pass 145 the threshold either. The gene BTNL2 encoded an MHC class II protein and was reported to be 146 associated with WBC, thus we considered this identified association was a worth-investigating 147 signal. The Manhattan plots for LDL-C and WBC were provided in Figures 5A-5B , respectively. 148 We additionally illustrated more details on the detected associations. Specifically, the 149 rs1801020 (F12)-APTT association was previously identified in GWAS analysis from the 150 BioBank Japan Project (BBJ), one of the largest EAS biobanks with over 160,000 subjects 151 (Kanai et al., 2018) . The gene F12 encodes coagulation factor XII that participates in the 152 initiation of blood coagulation, and mutation of F12 will cause prolonged coagulation time and 153 poor thromboplastin production (Zou et al., 2018) . The rs56393506 (LPA)-LpA association was 154 previously identified by GWAS in EUR population with over 13,781 individuals (Mack et al., 155 2017) but not in EAS population based on genomic studies. The gene LPA encodes a serine 156 proteinase that constitutes a substantial portion of lipoprotein(a) (McLean et al., 1987) . The lipid metabolism, and particular ApoE genotype results in a higher risk of elevated LDL-C levels. 165 The rs9268517-WBC is a novel genetic association identified by our GWAS analysis. However, 166 its closest gene BTNL2 was previously identified to be associated with WBC by a GWAS 167 analysis with 408,112 EUR individuals (Vuckovic et al., 2020) . The gene BTNL2 encodes MHC 168 II type I transmembrane protein, and binding to its receptor can inhibit T cell activation and 169 cytokine production.

The one-sample and two-sample MR analyses. In the Genome-wide association analysis of 171 laboratory features section, we identified many laboratory traits that were correlated to the 172 disease status. A natural question to ask was whether this correlation was also a causality. To 173 answer this question, we performed one-sample and two-sample MR analyses to examine 174 whether the traits had causal effects on COVID-19 disease. The one-sample MR results were 175 provided in Table S1 . After SNPs clumping and pruning, there was one SNP left in the analysis 176 for each trait. The Wald test p-values were all above 0.05, indicating no significant causal 177 relationships. We then performed two-sample MR study based on summary statistics calculated 178 from our datasets (Table S1 ). The results were similar to those of one-sample MR. Note that the 179 one-sample MR analyses cannot control for confounding factors very well and compared to 180 quantitative GWAS analysis, the case-control studies based on only a few hundred subjects have 181 low powers. 182 We instead conducted two-sample MR analyses with SNP-outcome summary statistics 183 obtained from the large-scale HGI database. For the SNP-exposure results, we used our dataset 184 as explore study and publicly available consortiums in EAS and EUR as replication studies. With 185 a significance level of 0.05, we identified four causal associations in the explore design (Table   186 S2), including WBC-B2 (p-value = 0.009), WBC-C2 (p-value = 0.024), LDL.C-B1 (p-value = 187 0.034), and apoA-B1 (p-value = 0.047). The valid instrumental variants for WBC, LDL-C, and 188 apoA were rs9268517 (BTNL2, HLA-DRA), rs7412 (ApoE), and rs11032789 (EHF), respectively. (Chen et al., 2020b ). First, we tested the causality of WBC counts based 204 on SNPs mapped to the MHC family, gene HLA-C (rs2524084, p-value = 1.260E-53). The 205 results were provided in Table S3 showing four causal associations on COVID-19 susceptibility 206 (HGI C2). These four causal effects were still significant after controlling the FDR at ≤5% and 207 suggested a candidate pathway that the MHC family affects disease susceptibility by regulating 208 WBC counts. Second, we did the MR analysis based on all WBC-associated SNPs in the 209 consortium. After SNPs clumping and harmonization with the HGI database, a total of 51 SNPs 210 were used in MR analysis based on different causal effect estimation methods (Table S4) . By 211 using IVW, WBC had two causal effects on COVID-19 susceptibility (HGI phenotype B2). The 212 scatter plot of SNP-WBC effects vs. SNP-B2 effects, the forest plot of MR causal effect for each 213 SNP, the funnel plot from single SNP analyses, and the leave-one-SNP-out plot from leave-one-214 out analysis were provided in Figure S3 . The MR-Egger p-value for testing heterogeneity is (Table S5) . However, the effect directions were not consistently positive or negative, implying complex genetic mechanisms of how the SNPs affected COVID-19 through LDL-C. The q-224 values of these associations are also less than 0.1 with two less than 0.05. Second, we did the MR 225 analysis based on all the LDL-C associated SNPs. After SNP clumping and harmonization with 226 the HGI database, 12 SNPs were used in MR with different causal effect estimation methods 227 (Table S6 ). The IVW method suggested two causal effects on COVID-19 susceptibility (HGI 228 C2). The scatter plot of SNP-LDL.C effects vs. SNP-C2 effects, the forest plot, the funnel plot, 229 and the leave-one-out plot were provided in Figure S4 . The MR-Egger p-value for testing (Table S7) , matching with the genetic 240 mechanisms in EAS population. After SNPs clumping and harmonization, 235 WBC-related 241 variants were used but no causal associations were significant based on the IVW method (Table   242 S8). The LDL-C summary results were obtained from a study with 431,167 subjects (Price et al., 243 2008). There was one SNP mapped to gene ApoE (rs1081105, p-value = 1.00E-200) and the 244 Wald ratio test did not identify causal effects (Table S9 ). With all 243 LDL.C-related SNPs after 245 clumping and harmonization, one causal association (HGI B2) was significant (p-value = 0.026) 246 (Table S10) . From these replication studies in EUR population, we identified similar functional 247 pathways that the MHC family influenced COVID-19 disease by controlling WBC counts. We 248 did not replicate the effects of ApoE on disease severity through LDL-C, but the MR analysis 249 based on all SNPs also suggested causality of LDL-C on COVID-19. HLA and susceptibility to COVID-19 (Nguyen et al., 2020) . The SARS-CoV-2 was found to 257 restrain antigen presentation and suppress immune reaction by regulating the expression of MHC 258 class in COVID-19 cases (Paces et al., 2020) . A causal effect could be considered as a risk 259 predictor of body experiencing acute immune response and the number of WBC rapidly 260 increased to against the virus. Previous studies showed that, as the disease progresses, mHLA-261 DR levels and lymphocyte cell counts varied in COVID-19 patients (Benlyamani et al., 2020 , 262 Zheng et al., 2020 . For the genetic pathways of how ApoE influenced disease status through 263 LDL-C, we raised a possible mechanism observed in our study and also reported by other studies.

Patients who carried ApoE ε4/ε4 genotype tend to be infected by SARS-CoV-2 and experience 265 severe symptoms from COVID-19 (Goldstein et al., 2020 , Kuo et al., 2020 . For example, a 266 study concluded that, among older people, patients with ApoE ε4/ε4 genotype had a much higher 267 risk of developing severe symptoms compared with ApoE ε3/ε3 (OR = 2.31, p-value = 1.19E-06) 268 (Kuo et al., 2020) . By investigating the ApoE genotypes in all 466 COVID-19 patients, we found 269 7 patients who carried ApoE ε4/ε4 in total, of which 5 patients were severe. Specifically, people 270 with ApoE ε4/ε4 have an increased risk of high cholesterol levels. When they are exposed to 271 SARS-CoV-2, the accumulation of cholesterol in alveolar epithelial cells increased the density of 272 lipid rafts, from which the virus binds to its target receptor ACE2. Therefore, a higher density of 273 lipid rafts facilitates the bindings in cell membranes and eventually raised the susceptibility to 274 SARS-CoV-2 infection and severity of COVID-19 (Goldstein et al., 2020 , Wang et al., 2020c , 275 Gkouskou et al., 2021 . The genetic mechanism is illustrated in Figure 5C .

Reverse MR analysis. In The one-sample and two-sample MR analyses section, we identified 277 two potential genetic pathways that the MHC complex and ApoE gene affected the COVID-19 278 vulnerability and severity by mediating WBC counts and cholesterol levels, respectively. We 279 were also interested in whether there existed functional mechanism that some instrumental SNPs 280 could alter laboratory traits through disease severity. In this section, we did not focus on one 281 COVID-19-related gene but used all associated SNPs. First, we used the HGI database as 282 exposure variable and laboratory traits as outcome from our dataset. The valid instrumental 283 variants corresponding to each exposure phenotype were provided and the MR results did not suggest potential causal effects of COVID-19 on WBC (Table S11) , indicating their phenotypic 285 correlations were not causalities trigged by genetic SNPs. For LDL-C, we did not obtain causal 286 effects of COVID-19 based on its associated SNPs (Table S12) . Then, we repeated the 287 examination by using UKBB dataset as outcome variable and had similar results (Table S13 for 288 WBC; Table S14 for LDL-C). These results implied that the COVID-19 related variants might 289 not be potential genetic factors that caused the correlation between disease severity and 290 laboratory traits. difficult to present all the dates. We instead divided the hospitalization days into several phases 363 for each patient. We only kept patients with more than two non-missing records and divided these records into two equal-length groups named early and late phases. At each phase, we took 365 the average of all available values for each feature and treated the mean as the patient's phase-366 wide measurement. We also defined the first and last non-missing measurements as an initial and 367 end record. In addition, we took the average of all non-missing records as the overall average. By 368 doing so, for each patient, we obtained trait values at five phases: initial, early, average, late, and 369 end. We first investigated the correlation between laboratory traits and disease status and 

Genome-wide association studies. We used PLINK v2.0 (Chang et al., 2015) to perform single-393 variant GWAS analyses using a linear regression model for the quantitative laboratory features 394 under the assumption of additive allelic effects of the SNP dosage. For each trait, we adjusted for 395 age, sex, and the top six principal components (PCs) of genetic ancestry and normalized the 396 resulting residuals by applying a Z-score normal transformation. The number of PCs was chosen 397 by using EIGENSTRAT software . We set a genome-398 wide significance threshold at the level of 5E-08 and a study-wide significance threshold at the 399 level of 6.41E-10 (=5E-08/78) by applying Bonferroni correction based on the number of 400 laboratory traits (n = 78).

The Host Genetics Initiative datasets. We used the HGI round 5 GWAS meta-analysis results. i.e., no horizontal pleiotropic effects of variants on the outcome. We performed both one-sample 418 and two-sample MR analyses. In the one-sample MR analysis, we used the individual-level 419 genotypic data, laboratory traits, and clinical severity from our own datasets. Specifically, we 420 used the R package AER (Zeileis, 2008) to conduct two-stage least squares (2SLS) method 421 (Burgess et al., 2017) . In 2SLS, the instrumental variables were used to obtain the predicted exposure with least squares estimates of effect sizes and the binary disease status was regressed 423 on the predicted values to estimate the causal effects based on the Wald test (Ludwig Fahrmeir, 424 2013).

The two-sample MR analyses require summary statistics from SNP-exposure and SNP-426 outcome association. We used the genetic variants that were strongly associated with laboratory 427 traits (p-value < 5E-08) to ensure the relevance assumption. We also removed the genome-wide 428 significant SNPs based on the SNP-outcome summary results to ensure the exclusion restriction 429 assumption. We first performed explore studies to discover potential causal relationships, and commonly used method is inverse variance weighted (IVW) . Other 448 methods included weighted median (Bowden et al., 2016) , simple mode, weighted mode 449 (Hartwig et al., 2017) , and MR-Egger (Bowden et al., 2015) . For causal effects identified by 450 IVW method, we also tested the heterogeneity and horizontal pleiotropy effects to examine 451 whether the MR results were valid. In details, we used MR-Egger method to test heterogeneity 452 (Bowden et al., 2015) and MR-PRESSO global test for horizontal pleiotropy (Verbanck et al., 507 Despite the many compelling discoveries of our work, there are still a few limitations.

First, the single-variant GWAS analysis of severity status did not identify any genome-wide 509 signals due to the current sample size (N = 466) and thus small genetic effect sizes. We believe 510 that large-scale case-control studies have potentials to uncover genome-wide significant variants. investigations and more reasonable interpretations were still needed to uncover the complicated 520 genetic impacts in COVID-19 disease susceptibility and severity. Forth, many genetic variants 521 influenced complex diseases by modulating gene expression and thus altering the abundance and 522 structure of proteins; these variants were also called eQTL (expression quantitative trait loci) and 523 pQTL (proteomic QTL), respectively (Gusev et al., 2016 , Chick et al., 2016 . In recent years, the 524 transcriptome-wide association studies (TWAS) and proteome-wide association studies (PWAS) 525 were developed and used to identify candidate genes whose regulated gene expressions and 526 proteins were associated with complex diseases (Gusev et al., 2016 , Gamazon et al., 2015 , Hu et 527 al., 2019 , Yuan et al., 2020 , Wingo et al., 2021 . The TWAS/PWAS analysis was essentially an 528 MR analysis with the exposure variable being gene expression/proteins. As the gene 529 expression/protein levels of COVID-19 patients in CHN population were available, 530 TWAS/PWAS analyses were worth investigating to uncover functional genes that influence 531 COVID-19 by regulating gene expression/proteins.

The authors declare no competing interests.

F.C. and X.J. conceived the study, designed the research program and managed the project. All authors participated in revising the manuscript.

(A) Pie diagrams for sex ratio and age distribution of 466 samples. (B) Bar charts for severity category and histogram of hospitalized days. In severity chart, the blue and green bars indicate the mild group, orange and red bars indicate the severe group. (C) Bar chart for the counts of severity in each age range. (D) Bar charts for the distributions of comorbidities and symptoms. For the comorbidities, HTN, CHD, BRN, TUM, SMK, CHB, COPD, HBV, ASM, TUB, and CKD indicate hypertension, coronary heart disease, brain infarction, tumor, smoking history, chronic bronchitis, chronic obstructive pulmonary disease, Hepatitis B virus, asthma, tuberculosis, and chronic kidney disease, respectively. For the symptoms, COU, FTG, CHT, APP, SPU, MUS, DIA, VOM, HDC, DIZ, THR, DYS, PAL, RHI, NEW, CHP, HEMO, ABD, and HEMO indicate cough, fatigue, chest tightness, poor appetite, sputum, muscle ache, diarrhea, vomiting, headache, dizziness, sore throat, dyspnea, palpitation, rhinorrhea, night sweating, chest pain, hemoptysis, abdominal pain, and hematemesis, respectively. Figures A-B show results of logistic regression analyses between laboratory features at five timepoints and disease severity and clinical outcome. The y-axis denotes -log10(p-value) multiplied by the effect direction (positive effect is 1 and negative effect is -1). We used red dashed line to denote y=0. A line below (above) the red dashed line indicates a negative (positive) correlation. The blue dashed line denotes the horizontal line y= ± -log10(0.05)= ± 1.3. Figures C-I are boxplots of three patients' group: mild (red), recovery (light green), and death (pink). Patients in mild group were diagnosed as mild and recovered, patients in recovery group were diagnosed as severe and recovered, and patients in death group were diagnosed as severe and dead. The light blue backgrounds represent the normal range of each laboratory trait. The y-axis denotes the quantities of each trait. We performed two-sample t-test for each pair of groups at different significances of 0.05 (*), 0.01 (**), and 0.001 (***).

We performed SNP-based GWAS analyses for 78 laboratory traits and employed significant SNP-trait associations for further MR analyses to investigate the causality of laboratory traits on COVID-19 disease. Based on the single SNP case-control GWAS studies of COVID-19 severity, we conducted gene-based and pathway analyses to uncover functional pathways. 

(A-B) Manhattan plot of the GWAS single-variant test results of WBC and LDL-C. The red dash line indicates the genome-wide significance threshold 5E-8. (C) Genetic mechanisms of how the MHC complex and ApoE genotype influences the COVID-19 susceptibility and severity through WBC counts and cholesterol levels. For WBC, the MHC complex encoded HLA to activate T lymphocyte cells and natural killer cells to against the SARS-CoV-2, reflecting on increased numbers of WBC. A causal effect could be considered as a risk predictor of body experiencing acute immune response. As the response abilities were different, people experienced different symptoms. For cholesterol level, people with ApoE e4 have an increased risk of high cholesterol levels. When they are exposed to SARS-CoV-2, the accumulation of cholesterol in alveolar epithelial cells increased the density of lipid rafts, from which the virus binds to its target receptor ACE2. Therefore, a higher density of lipid rafts facilitates the bindings in cell membranes and eventually raised the susceptibility to SARS-CoV-2 infection and severity of COVID-19. Table S1 . Seven top SNP-trait significant associations and the corresponding one-sample and two-sample MR results with COVID-19 severity obtained from our dataset, related to Figure 4 . Table S2 . Two-sample MR results with SNP-exposure summary statistics from our dataset and SNP-outcome summary statistics from HGI database, related to Figure 4 . Table S3 . Two-sample MR results based on one WBC-associated SNP in gene HLA-C from an EAS study and SNP-outcome summary statistics from HGI database, related to Figure 5 . Table S4 . Summary statistics of a list of WBC-related SNPs in an EAS population and their associations in HGI and the corresponding two-sample MR results, related to Figure 5 . Table S5 . Two-sample MR results based on one LDL.C-associated SNP in gene ApoE from an EAS study and SNP-outcome summary statistics from HGI database, related to Figure 5 . Table S6 . Summary statistics of a list of LDL.C-related SNPs in an EAS population and their associations in HGI and the corresponding two-sample MR results, related to Figure 5 . Table S7 . Two-sample MR results based on one WBC-associated SNP in gene HLA-DPA1/HLA-DPB1 from an EUR study and SNP-outcome summary statistics from HGI database, related to Figure 5 . Table S8 . Summary statistics of a list of WBC-related SNPs in an EUR population and their associations in HGI and the corresponding two-sample MR results, related to Figure 5 . Table S9 . Two-sample MR results based on one LDL.C-associated SNP in gene ApoE from an EUR study and SNP-outcome summary statistics from HGI database, related to Figure 5 . Table S10 . Summary statistics of a list of LDL.C-related SNPs in an EUR population and their associations in HGI and the corresponding two-sample MR results, related to Figure 5 . Table S11 . Summary statistics of a list of COVID19-related SNPs from the HGI database and their associations with WBC in our dataset and the corresponding two-sample MR results, related to Table 3 . Table S12 . Summary statistics of a list of COVID19-related SNPs from the HGI database and their associations with LDL-C in our dataset and the corresponding two-sample MR results, related to Table 3 . J o u r n a l P r e -p r o o f

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)

Dysregulation of type I interferon responses in COVID-19

Gene ontology: tool for the unification of biology

The control of the false discovery rate in multiple testing under dependency

Monocyte HLA-DR Measurement by Flow Cytometry in COVID-19 Patients: An Interim Review

Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression

Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator

Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering

Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods

A review of instrumental variable estimators for Mendelian randomization

Secondgeneration PLINK: rising to the challenge of larger and richer datasets

CNGBdb: China National GeneBank DataBase

Defining the consequences of genetic variation on a proteome-wide scale

COVID-19 and comorbidities: Deleterious impact on infected patients

A gene-based association method for mapping traits using reference transcriptome data

COVID-19 enters the expanding network of apolipoprotein E4-related pathologies

Does apolipoprotein E genotype predict COVID-19 severity?

CNSA: a data repository for archiving omics data

Integrative approaches for largescale transcriptome-wide association studies

COVID-19 and Sex Differences: Mechanisms and Biomarkers

Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption

Orienting the causal relationship between imprecisely measured traits using GWAS summary data

The MR-Base platform supports systematic

A statistical framework for cross-tissue transcriptome-wide association analysis

Gender Differences in Patients With COVID-19: Focus on Severity and Mortality

Covid-19: risk factors for severe disease and death

Reactome: a knowledgebase of biological pathways

Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases

KEGG: kyoto encyclopedia of genes and genomes

APOE e4 Genotype Predicts Severe COVID-19 in the UK Biobank Community Cohort

Risk factors for predicting mortality in elderly patients with COVID-19: A review of clinical data in China

UK Biobank -Neale lab

Type I interferon: From innate response to treatment for COVID-19

Regression: Models, Methods and Applications

A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms

Robust relationship inference in genome-wide association studies

cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

VEGAS2: Software for More Flexible Gene-Based Testing

Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2

COVID-19 and the immune system

Population structure and eigenanalysis

WikiPathways: pathway editing for the people

Principal components analysis corrects for stratification in genome-wide association studies

FTO gene SNPs associated with extreme obesity in cases, controls and extremely discordant sister pairs

g:Profiler--a web-based toolset for functional profiling of gene lists from large-scale experiments

Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity

Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases

Mendelian randomization: use of genetics to enable causal inference in observational studies

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility

The role of high cholesterol in age-related COVID19 lethality

Brain proteomewide association study implicates novel proteins in depression pathogenesis

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

rMVP: A Memory-efficient, Visualization-enhanced, and Parallel-accelerated tool for Genome-Wide Association Study

Testing and controlling for horizontal pleiotropy with probabilistic Mendelian randomization in transcriptome-wide association studies

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Genetic analysis of a novel missense mutation (Gly542Ser) with factor XII deficiency in a Chinese patient of consanguineous marriage

Notes. AF indicates the allele frequency for the effect/alternate allele; R2 indicates the imputation score based on EAS population from the 1KGP; N is the sample size used in GWAS analysis; "√" and "X" indicate the corresponding associations were previously reported and not reported in a population based on genomic studies, respectively. Notes. A1 denotes the effect/alternate allele. 1KGP EAS Freq indicates the allele frequency in EAS population from the 1KGP. Mild Freq indicates the allele frequency in patients from mild and moderate (grouped into mild) groups. Severe Freq indicates the allele frequency in patients from severe and critical (grouped into severe) groups.